Global posting trends and status
From 1942 to 2000, the overall number of articles published was relatively low, with no significant upward trend. Since 2000, the number of articles published on thrombosis in lung cancer has gradually increased, peaking in 2020, as has the average number of citations per article, which peaked between 2000 and 2022 (Fig. 1A). This shows that research on thrombosis in lung cancer has been gaining attention from researchers over the last 20 years. China and the United States have published the largest amount of literature on thrombosis in lung cancer (Fig. 1B).
Distribution of authors and journals
The most productive authors and journals (Table 1) include the authors “ZHANG Y,” “YANG Y,” “LI Y,” “WANG Y,” and the journals “THROMBOSIS RESEARCH,” “LUNG CANCER,” “CLINICAL LUNG CANCER,” and “ONCOLOGIST.” These journals are mainly oncology journals; the authors are mainly from China, and they collaborate closely (Fig. 2), often co-authoring important articles. They also appear in the influence rankings (Table 2). In terms of citation frequency, the most frequently cited journals include “JOURNAL OF CLINICAL ONCOLOGY,” “JOURNAL OF THROMBOSIS HAEMOSTASIS,” “THE NEW ENGLAND JOURNAL OF MEDICINE,” “BLOOD,” and “THROMBOSIS RESEARCH.” These journals focus more on blood thrombosis. The top authors in terms of citation frequency include “OSANTO S,” “BLOM JW,” “ROSENDAAL FR,” “DOGGEN CJM,” and “KHORANA AA” (Table 3).
Table 1: The highest-ranked journals and authors
Terms
|
Articles
|
Description
|
THROMBOSIS RESEARCH
|
18
|
Source
|
LUNG CANCER
|
16
|
Source
|
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
|
7
|
Source
|
CLINICAL LUNG CANCER
|
7
|
Source
|
ONCOLOGIST
|
7
|
Source
|
CAPITAL MED UNIV
|
30
|
Affiliation
|
TONGJI UNIV
|
27
|
Affiliation
|
UNIV ROCHESTER
|
22
|
Affiliation
|
PETER MACCALLUM CANC CTR
|
21
|
Affiliation
|
SHANGHAI JIAO TONG UNIV
|
18
|
Affiliation
|
ZHANG Y
|
13
|
Author
|
LI J
|
8
|
Author
|
LI Y
|
8
|
Author
|
YANG Y
|
8
|
Author
|
WANG Y
|
7
|
Author
|
Table 2: The most influential journals and authors
Element
|
H_index
|
G_index
|
M_index
|
TC
|
NP
|
PY_start
|
LUNG CANCER
|
12
|
16
|
0.632
|
450
|
16
|
2004
|
THROMBOSIS RESEARCH
|
11
|
16
|
0.846
|
262
|
17
|
2010
|
CLINICAL LUNG CANCER
|
7
|
7
|
0.412
|
251
|
7
|
2006
|
ONCOLOGIST
|
7
|
7
|
0.368
|
668
|
7
|
2004
|
CANCER
|
6
|
6
|
0.333
|
627
|
6
|
2005
|
ZHANG Y
|
8
|
13
|
-
|
193
|
13
|
-
|
KHORANA AA
|
6
|
6
|
0.333
|
892
|
6
|
2005
|
YANG Y
|
6
|
8
|
0.545
|
163
|
8
|
2012
|
LI Y
|
5
|
6
|
-
|
42
|
7
|
-
|
WANG Y
|
5
|
6
|
0.5
|
187
|
6
|
2013
|
H index is a mixed quantitative index, which can be used to evaluate the number and level of academic output of researchers.
G index is a derivative index of H index, which mainly makes up for the defect that H index can't reflect highly cited papers well.
M index is used to measure the increasing speed of H index over time, reflecting the output and future potential of a scientific researcher.
TC: total citations; NP: number of publications; PY: publication year first indexed
Table 3: The most cited journals and authors
Terms
|
Total citations
|
Description
|
USA
|
3446
|
Country
|
THE NETHERLANDS
|
1612
|
Country
|
CANADA
|
858
|
Country
|
CHINA
|
719
|
Country
|
ITALY
|
590
|
Country
|
J CLIN ONCOL
|
687
|
Source
|
J THROMB HAEMOST
|
585
|
Source
|
NEW ENGL J MED
|
504
|
Source
|
BLOOD
|
379
|
Source
|
THROMB RES
|
364
|
Source
|
OSANTO S
|
140
|
Author
|
BLOM JW
|
115
|
Author
|
ROSENDAAL FR
|
115
|
Author
|
DOGGEN CJM
|
66
|
Author
|
KHORANA AA
|
62
|
Author
|
Top 10 highly cited articles
Table 4 shows the most globally cited publications in the field of thrombosis in lung cancer from 1942 to 2022. This includes many publications before 2010, mainly related to the study of the relationship between cancer and venous thrombosis and the exploration of cancer-related thrombosis risk factors.
Table 4: The most cited documents
Paper
|
DOI
|
Total Citations (TC)
|
TC per year
|
Normalized TC
|
BLOM JW, 2005, JAMA-J AM MED ASSOC
|
10.1001/jama.293.6.715
|
1295
|
71.94
|
5.33
|
LEE AYY, 2003, CIRCULATION
|
10.1161/01.CIR.0000078466.72504.AC
|
519
|
25.95
|
5.00
|
KHORANA AA, 2005, CANCER
|
10.1002/cncr.21496
|
390
|
21.67
|
1.60
|
KHORANA AA, 2006, J CLIN ONCOL
|
10.1200/JCO.2005.03.8877
|
333
|
19.59
|
3.61
|
COHEN MH, 2007, ONCOLOGIST
|
10.1634/theoncologist.12-6-713
|
306
|
19.13
|
3.96
|
FANUCCHI M, 1997, N ENGL J MED
|
10.1056/NEJM199702063360603
|
231
|
8.88
|
1.00
|
CRINO L, 2010, LANCET ONCOL
|
10.1016/S1470-2045(10)70151-0
|
210
|
16.15
|
4.60
|
CHEW HK, 2008, J THROMB HAEMOST
|
10.1111/j.1538-7836.2008.02908.x
|
195
|
13.00
|
2.23
|
BLOM JW, 2004, J THROMB HAEMOST
|
10.1111/j.1538-7836.2004.00928.x
|
152
|
8.00
|
2.80
|
NUMICO G, 2005, CANCER
|
10.1002/cncr.20893
|
145
|
8.06
|
0.60
|
Normalized TC (Normalized Total Citations): the Normalized TC is calculated to provide equal credit of citation to all the authors of the paper
Keyword analysis
We conducted a keyword analysis of the 378 included documents, and the word clouds (Fig. 3A–B) shows the keywords that appeared most frequently, including “lung cancer,” “thrombosis,” and “pulmonary embolism,” and the additional keywords with the highest frequency, which included “thrombosis,” “chemotherapy,” “risk,” “prevention,” and “survival.” It is evident that risk factor exploration and chemotherapy have become topics of interest. The keyword co-occurrence network results show that themes around the concepts of “chemotherapy,” “risk,” “prevention,” and “survival” are emerging in the field of thrombosis in lung cancer, forming four major components of research on thrombosis in lung cancer (Fig. 4). The conceptual structure of the diagram suggests that the current literature in the field of thrombosis in lung cancer can be divided into two directions, and the midpoint of the region suggests that these two directions can be roughly composed of two directions for lung cancer thrombotic events, as well as lung cancer itself (Fig. 5).
Based on the keyword clustering, we created a strategic coordinates map (Fig. 6). This was constructed as a two-dimensional diagram with density as the vertical coordinate and centripetalism as the horizontal coordinate. The higher the density value of a topic, the higher the maturity of the topic. The centripetal index represents the strength of the linkage between a topic and other topics. The high centrality and density of ROS1, pneumonectomy, disseminated intravascular coagulation, and lung neoplasm in quadrant I indicate that these terms are highly mature and have extensive associations with other topics. However, disseminated intravascular coagulation and lung neoplasm as disease attribute terms appeared, which may be controversial. The terms infarction, pulmonary embolus, and docetaxel are located in quadrant II, with high density and low centrality. This indicates that the research content is relatively mature but not closely related to other subject terms. The lowest centrality and density value of bevacizumab and neoplasms in quadrant III indicates that these subject terms are not closely related to other subject terms and have low maturity, so it is a relatively spot. In the quadrant IV, lung cancer, cancer, thrombosis, and thromboembolism are widely associated with other terms and belong to the basic themes with low maturity (Fig. 6).
As shown in the research hotspot diagram (Fig. 7), the prediction of risk factors for thrombotic events in lung cancer remains a popular topic in thrombosis in lung cancer. At the same time, new hot terms, such as immunotherapy, immune checkpoint inhibitors, and ROS1, Have emerged, suggesting that these are the most popular terms in thrombosis in lung cancer. This indicates that immunotherapy and ROS1-related driver genes are gradually emerging in the field of thrombosis in lung cancer.
Table 5: Clustering results of keywords plus
Keyword plus
|
Cluster
|
thrombosis
|
1
|
chemotherapy
|
1
|
risk
|
1
|
venous thromboembolism
|
1
|
pulmonary embolism
|
1
|
risk factors
|
1
|
cancer
|
1
|
thromboembolism
|
1
|
prevention
|
1
|
molecular weight heparin
|
1
|
survival
|
1
|
carcinoma
|
1
|
events
|
1
|
management
|
1
|
prophylaxis
|
1
|
therapy
|
1
|
malignancy
|
1
|
disease
|
1
|
thromboprophylaxis
|
1
|
validation
|
1
|
complications
|
1
|
cohort
|
1
|
diagnosis
|
1
|
tissue factor
|
1
|
cisplatin
|
2
|
epidemiology
|
1
|
coagulation
|
1
|
expression
|
1
|
surgery
|
1
|
trial
|
2
|
cancer patients
|
1
|
gemcitabine
|
2
|
prevalence
|
1
|
VTE
|
1
|
predictors
|
1
|
lung cancer
|
1
|
mortality
|
1
|
randomized trial
|
1
|
adenocarcinoma
|
1
|
angiogenesis
|
2
|
carboplatin
|
2
|
venous
|
1
|
warfarin
|
1
|
breast cancer
|
1
|
guidelines
|
1
|
Meta-analysis
|
1
|
open label
|
2
|
paclitaxel
|
2
|
combination
|
2
|
embolism
|
1
|
endothelial growth factor
|
2
|
frequency
|
1
|
metastasis
|
1
|
prognosis
|
1
|
tissue factor expression
|
2
|
American society
|
1
|
bevacizumab
|
1
|
D dimer
|
1
|
docetaxel
|
2
|
heparin
|
1
|
impact
|
1
|
mechanisms
|
1
|
outcomes
|
1
|
patients receiving chemotherapy
|
1
|
population
|
1
|
recurrent venous thromboembolism
|
1
|
trousseaus syndrome
|
1
|
venous thrombosis
|
1
|
Vienna cancer
|
1
|
ambulatory patients
|
1
|
anticoagulation
|
1
|
colorectal cancer
|
2
|
guideline
|
1
|
mutations
|
1
|
patient
|
1
|
patterns
|
1
|
phase iii trial
|
2
|
safety
|
1
|
activation
|
1
|
association
|
1
|
bleeding complications
|
1
|
cell lung cancer
|
1
|
CT
|
1
|
deep vein
|
1
|
deep venous thrombosis
|
1
|
efficacy
|
1
|
enoxaparin
|
1
|
extension
|
1
|
gene
|
1
|
identification
|
1
|
ischemic stroke
|
1
|
lobectomy
|
1
|
multicenter
|
1
|
obstruction
|
1
|
pathophysiology
|
1
|
prediction
|
1
|
pulmonary vein stump
|
1
|
rates
|
1
|
receiving chemotherapy
|
1
|
resection
|
1
|
solid tumors
|
1
|
thromboembolic events
|
1
|
tumor
|
1
|